Breast Cancer

A breast cancer survivor who opted for a unilateral mastectomy advises people to look at all treatment and risk reduction options when first diagnosed with breast cancer so they can avoid any regrets years later.

View the full CURE Educated Patient Breast Cancer Summit on demand.

A roundup of some of the latest news and updates for patients with breast cancer from CURE®

Last week, the Food and Drug Administration (FDA) was scheduled to make a decision on whether or not they would approve oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. The agency decided not to approve the regimen, and issued a complete response letter outlining why.

Even as chemotherapy, surgery and radiation remain treatment mainstays, immunotherapy is ready to take the stage.

Patients with prostate and breast cancer may be unknowingly putting themselves at risk while taking herbs and supplements during chemotherapy and should consult their medical team before using them, according to an expert.

A patient with metastatic breast cancer recalls how she’s been told countless times that she’s so brave, so strong and so resilient. Here, she thanks those who have influenced her and helped her be so courageous.

Although most patients reported satisfaction after undergoing a mastectomy without breast reconstruction surgery, 20.7% of women felt that their surgeon was not supportive of their decision to do so.

A cancer diagnosis often comes with concerns of what’s next for patients. One concern is how they’re going to afford their treatments. Here, a panel of experts discuss what options are available.

There are two myths that patients with cancer believe when it comes to being health advocates. Here, a panel of experts look to dispel those myths to help patients become better advocates.

Breast cancer survivor and Evofem Biosciences founder and CEO Saundra Pelletier shares her thoughts on a new hormone-free contraceptive gel that could improve sexual quality of life in patients with cancer.

There are several health equity barriers in patients with cancer, one of which involves adequate access to clinical trials. Here, a panel of experts and a cancer survivor discuss ways to improve access.

The Society of Breast Imaging has recommended women wait four to six weeks after receiving their second dose of a COVID-19 vaccine to get a screening mammogram. However, experts differ on whether women should wait to get a screening mammogram following their vaccine.

This week on the “CURE® Talks Cancer” podcast, we spoke with Evofem Biosciences founder and CEO Saundra Pelletier about what it was like to go through the shock of receiving a cancer diagnosis while also navigating a career, and explaining how her product, which is now FDA-approved, can help patients with cancer and survivors improve their sexual quality of life.

Ahead of the release of their book, “Off Our Chests”, Dr. John Marshall and his wife, Liza, look back on the trials and tribulations of Liza’s triple-negative breast cancer diagnosis – from the perspective of a patient and her husband, the caregiver and oncologist.

Patents with HER2-positive breast cancer had a similar rate of overall survival with Perjeta plus chemotherapy and trastuzumab compared with placebo plus chemotherapy and trastuzumab, although longer follow-up is needed to determine whether a benefit exists in that area.

A cancer survivor pens an ode to her port that has made her journey much less stressful.

A patient with cancer recalls how the love her care team showed her during her treatment made such a difference in her journey to recovery. Her hope: That more patients with cancer around the world can find doctors who treat them as a person, and not just a case.

Moment by moment, we move toward life. We feel what needs to be felt. We can even feel through the numb parts—the broken pieces. Instead of looking somewhere else, we look straight on— at ourselves and others. We see what’s really there. Who is there for us? Who is not? We choose to be with those we love, and those who love us back—like the person in the mirror, the new friend.

Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S.

An interim analysis of the PALLAS study showed that adding Ibrance to endocrine therapy, compared to endocrine therapy alone, after initial treatment ended for patients with HR-positive, HER2-negative, early-stage breast cancer did not extend the length of time before a patient’s disease recurred.